Strengthening R&D centered on sharing challenges and co-creation with customers
First written in FY2016. 19 of 31 entries say "Restated". Latest entry: FY2026.
19 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「This will accelerate the development of physical AI and the deployment of its technologies across the business to address operational challenges, such as understanding equipment conditions and improving maintenance planning, thereby contributing to the transformation of social infrastructure.」
The Group expanded its R&D priorities beyond Lumada 3.0 and HMAX to IWIM, an integrated physical AI model that learns operational and maintenance knowledge for social infrastructure. - 2026-04-27AdvancedEarnings presentation
「Promote the development of new businesses and technologies that will drive the next phase of growth」
Energy solutions, the use of space-based big data and silicon quantum computing were disclosed as examples of new business and technology development. - FY2026-H1RestatedAnnual report
「In the current interim consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the current interim consolidated fiscal year were ¥125.3 billion, equivalent to 2.6% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group reported interim R&D expenses of 2.6% of revenue, or ¥125.3 billion. - FY2025AdvancedAnnual report
「The Group's R&D expenses for the current consolidated fiscal year were ¥259.4 billion, equivalent to 2.7% of revenue,」
The Group disclosed R&D expenses of ¥259.4 billion, equivalent to 2.7% of revenue, and pursued R&D in digital and green innovation, generative AI, quantum technologies and hydrogen production, among other areas. - FY2025-H1RestatedAnnual report
「In the current interim consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year.」
The Group reaffirmed that there had been no material changes to its R&D policy. - FY2024AdvancedAnnual report
「The Group's R&D expenses for the current consolidated fiscal year were ¥290.1 billion, equivalent to 3.0% of revenue,」
The Group disclosed R&D expenses of ¥290.1 billion, equivalent to 3.0% of revenue. It planned to invest approximately ¥100.0 billion in advanced research over the three-year period of the 2024 Mid-term Management Plan and demonstrated results in generative AI, field-augmented metaverse, EV charging and semiconductor measurement. - FY2024-Q2RestatedAnnual report
「In the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year.」
The Group reaffirmed that there had been no material changes to its R&D policy. - FY2023AdvancedAnnual report
「To accelerate global growth through its Social Innovation Business, the Group reorganized its R&D organization in April 2022. It integrated the Center for Social Innovation Co-creation, which had worked with Hitachi's front-line operations to create value-driven innovation, and the Center for Technology Innovation, which had developed world-leading technologies supporting value creation, and reorganized them into the Digital Services Research Division and the Sustainability Research Division, strengthening value creation through DX and GX (green transformation).」
The Group reorganized its R&D organization into the Digital Services Research Division and the Sustainability Research Division, advancing its R&D structure around DX and GX. - FY2023-Q3RestatedAnnual report
「In the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative third quarter were ¥232.4 billion, equivalent to 2.9% of revenue, broken down as follows.」
The Group reaffirmed that there had been no material changes to its R&D policy. Cumulative third-quarter R&D expenses were 2.9% of revenue, or ¥232.4 billion. - FY2023-Q1RestatedAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year.」
The Group reaffirmed that there had been no material changes to its R&D policy. - FY2022AdvancedAnnual report
「In addition to collaborating with universities and other research institutions in Japan and overseas, the Group has actively strengthened collaboration with startups by establishing its Corporate Venturing Office in April 2019 and its second fund in October 2021.」
In addition to R&D originating from customer and social challenges, the Group developed concrete startup collaboration initiatives through its Corporate Venturing Office and second fund. - FY2022-Q3RestatedAnnual report
「In the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative third quarter were ¥228.8 billion, equivalent to 3.1% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group reported cumulative third-quarter R&D expenses of 3.1% of revenue, or ¥228.8 billion. - FY2022-Q1RestatedAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative first quarter were ¥75.4 billion, equivalent to 3.2% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group reported first-quarter R&D expenses of 3.2% of revenue, or ¥75.4 billion. - FY2021AdvancedAnnual report
「In February 2021, the Group also formulated its AI Ethics Principles to develop and deploy human-centered AI in society as part of its Social Innovation Business, driven by Lumada, thereby further promoting R&D that contributes to resolving customer challenges.」
In addition to R&D originating from customer challenges, the Group formulated AI Ethics Principles for the development and social deployment of human-centered AI. - FY2021-Q1RestatedAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative first quarter were ¥56.3 billion, equivalent to 3.5% of revenue, broken down as follows.」
There were no material changes to the R&D policy covering customer challenges, global products and services, Lumada core technologies and advanced research. First-quarter R&D expenses were 3.5% of revenue, or ¥56.3 billion. - FY2020AdvancedAnnual report
「To strengthen the global competitiveness of its business activities, the Group is pursuing R&D focused on identifying, sharing and resolving customer challenges, developing strong products and services that lead the globalization of its businesses, and strengthening core technologies to expand the Lumada business. In addition, the Group is pursuing advanced research to develop future core businesses.」
The Group identified customer challenges, global products and services, Lumada core technologies and advanced research as priority R&D areas. R&D expenses were 3.4% of revenue, or ¥293.7 billion. - FY2020-Q3RestatedAnnual report
「In the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative third quarter were ¥212.4 billion, equivalent to 3.3% of revenue, broken down as follows.」
There were no material changes to the R&D policy centered on identifying, sharing and resolving customer challenges. R&D expenses were 3.3% of revenue, or ¥212.4 billion. - FY2020-Q2RestatedAnnual report
「In the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative second quarter were ¥142.2 billion, equivalent to 3.4% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group continued R&D focused on identifying, sharing and resolving customer challenges. - FY2020-Q1RestatedAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative first quarter were ¥68.3 billion, equivalent to 3.4% of revenue, broken down as follows.」
The Group reaffirmed that there had been no material changes to its R&D policy and reported first-quarter R&D expenses of 3.4% of revenue, or ¥68.3 billion. - FY2019AdvancedAnnual report
「The Group is strengthening R&D focused on identifying, sharing and resolving customer challenges, as well as developing strong products and services that lead the globalization of its businesses.」
The Group continued its R&D policy focused on identifying, sharing and resolving customer challenges and global expansion, and demonstrated development results in biometric authentication, CMOS annealing and coordinated control of multiple AI systems. - FY2019-Q3RestatedAnnual report
「In the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative third quarter were ¥234.1 billion, equivalent to 3.5% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group reported R&D expenses of 3.5% of revenue, or ¥234.1 billion. - FY2019-Q2RestatedAnnual report
「In the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative second quarter were ¥156.5 billion, equivalent to 3.5% of revenue, broken down as follows.」
The Group reaffirmed that there had been no material changes to its R&D policy and reported cumulative second-quarter R&D expenses of 3.5% of revenue, or ¥156.5 billion. - FY2019-Q1RestatedAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year.」
The Group reaffirmed that there had been no material changes to its R&D policy. R&D expenses were 3.5% of revenue, or ¥75.4 billion. - FY2018AdvancedAnnual report
「To strengthen the global competitiveness of its business activities, the Group is strengthening R&D focused on identifying, sharing and resolving customer challenges, as well as developing strong products and services that lead the globalization of its businesses.」
The Group continued R&D centered on identifying, sharing and resolving customer challenges, and demonstrated specific results in AI, IoT quality control and medical measurement. Annual R&D expenses were 3.6% of revenue, or ¥332.9 billion. - FY2018-Q3RestatedAnnual report
「In the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year.」
The Group reaffirmed that there had been no material changes to its R&D policy. - FY2018-Q2RestatedAnnual report
「In the cumulative second quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year.」
The Group reaffirmed that there had been no material changes to its R&D policy. R&D expenses were 3.7% of revenue, or ¥162.2 billion. - FY2018-Q1RestatedAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative first quarter were ¥74.2 billion, equivalent to 3.6% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group reported R&D expenses of 3.6% of revenue, or ¥74.2 billion. - FY2017AdvancedAnnual report
「The Group's R&D expenses for the current consolidated fiscal year were ¥323.9 billion, equivalent to 3.5% of revenue, with R&D expenses by segment as follows.」
The Group continued R&D focused on identifying, sharing and resolving customer challenges, and demonstrated specific development results in AI, robotics, authentication and video analysis, among other areas. Annual R&D expenses were 3.5% of revenue, or ¥323.9 billion. - FY2017-Q3RestatedAnnual report
「In the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the status of the Group's R&D activities described in the annual securities report for the previous fiscal year. The Group's R&D expenses for the cumulative third quarter were ¥234.9 billion, equivalent to 3.6% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group reported cumulative third-quarter R&D expenses of 3.6% of revenue, or ¥234.9 billion. - FY2017-Q1RestatedAnnual report
「In the first quarter of the current consolidated fiscal year, the Group's R&D expenses were ¥76.4 billion, equivalent to 3.6% of revenue, broken down as follows.」
While stating that there had been no material changes to its R&D policy, the Group reported quarterly R&D expenses of 3.6% of revenue, or ¥76.4 billion. - FY2016First statedAnnual report
「The Group will further strengthen the role of R&D in improving profitability by reinforcing R&D that shares challenges with customers and jointly creates new solutions.」
The Group is prioritizing its Social Innovation Business, customer co-creation and the reorganization of its research bases in Japan and overseas. R&D expenses were 3.3% of revenue, or ¥333.7 billion.